Literature DB >> 24757155

Assessment of joint and fascia manifestations in chronic graft-versus-host disease.

Yoshihiro Inamoto1, Joseph Pidala, Xiaoyu Chai, Brenda F Kurland, Daniel Weisdorf, Mary E D Flowers, Jeanne Palmer, Sally Arai, David Jacobsohn, Corey Cutler, Madan Jagasia, Jenna D Goldberg, Paul J Martin, Steven Z Pavletic, Georgia B Vogelsang, Stephanie J Lee, Paul A Carpenter.   

Abstract

OBJECTIVE: To investigate the usefulness of various scales for evaluating joint and fascia manifestations in patients with chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic cell transplantation, and to compare the scales in terms of simplicity of use and ability to yield reliable and clinically meaningful results.
METHODS: In a prospective, multicenter, longitudinal, observational cohort of patients with chronic GVHD (n = 567), we evaluated 3 scales proposed for assessing joint status: the National Institutes of Health (NIH) joint/fascia scale, the Hopkins fascia scale, and the Photographic Range of Motion (P-ROM) scale. Ten other scales were also tested for assessment of symptoms, quality of life, and physical functions.
RESULTS: Joint and fascia manifestations were present at study enrollment in 164 (29%) of the patients. Limited range of motion was most frequent at the wrists or fingers. Among the 3 joint assessment scales, changes in the NIH scale correlated with both clinician- and patient-perceived improvement of joint and fascia manifestations, with higher sensitivity than the Hopkins fascia scale. Changes in all 3 scales correlated with clinician- and patient-perceived worsening, but the P-ROM scale was the most sensitive in this regard. Onset of joint and fascia manifestations was not associated with subsequent mortality.
CONCLUSION: Joint and fascia manifestations are common in patients with chronic GVHD and should be assessed carefully in these patients. Our results support the use of the NIH joint/fascia scale and P-ROM scale to assess joint and fascia manifestations. The NIH scale better captures improvement, while the P-ROM scale better captures worsening. The utility of these scales could also be tested in the rheumatic diseases.
Copyright © 2014 by the American College of Rheumatology.

Entities:  

Mesh:

Year:  2014        PMID: 24757155      PMCID: PMC4014356          DOI: 10.1002/art.38293

Source DB:  PubMed          Journal:  Arthritis Rheumatol        ISSN: 2326-5191            Impact factor:   10.995


  25 in total

Review 1.  Bone-marrow transplantation (first of two parts).

Authors:  E Thomas; R Storb; R A Clift; A Fefer; F L Johnson; P E Neiman; K G Lerner; H Glucksberg; C D Buckner
Journal:  N Engl J Med       Date:  1975-04-17       Impact factor: 91.245

2.  Diffuse fasciitis after bone marrow transplantation.

Authors:  V van den Bergh; G Tricot; G Fonteyn; R Dom; J Bulcke
Journal:  Am J Med       Date:  1987-07       Impact factor: 4.965

3.  Energy-speed relationship of walking: standard tables.

Authors:  R L Waters; B R Lunsford; J Perry; R Byrd
Journal:  J Orthop Res       Date:  1988       Impact factor: 3.494

4.  Reliability and validity of grip and pinch strength evaluations.

Authors:  V Mathiowetz; K Weber; G Volland; N Kashman
Journal:  J Hand Surg Am       Date:  1984-03       Impact factor: 2.230

5.  Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation.

Authors:  K M Sullivan; R P Witherspoon; R Storb; P Weiden; N Flournoy; S Dahlberg; H J Deeg; J E Sanders; K C Doney; F R Appelbaum
Journal:  Blood       Date:  1988-08       Impact factor: 22.113

6.  Sclerotic-type chronic GVHD of the skin: clinical risk factors, laboratory markers, and burden of disease.

Authors:  Kathryn J Martires; Kristin Baird; Seth M Steinberg; Lana Grkovic; Galen O Joe; Kirsten M Williams; Sandra A Mitchell; Manuel Datiles; Fran T Hakim; Steven Z Pavletic; Edward W Cowen
Journal:  Blood       Date:  2011-07-26       Impact factor: 22.113

7.  Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory.

Authors:  C S Cleeland; T R Mendoza; X S Wang; C Chou; M T Harle; M Morrissey; M C Engstrom
Journal:  Cancer       Date:  2000-10-01       Impact factor: 6.860

8.  Development and validation of a scale to measure symptoms of chronic graft-versus-host disease.

Authors:  Stephanie k Lee; E Francis Cook; Robert Soiffer; Joseph H Antin
Journal:  Biol Blood Marrow Transplant       Date:  2002       Impact factor: 5.742

9.  Predictors of death from chronic graft-versus-host disease after bone marrow transplantation.

Authors:  J R Wingard; S Piantadosi; G B Vogelsang; E R Farmer; D A Jabs; L S Levin; W E Beschorner; R A Cahill; D F Miller; D Harrison
Journal:  Blood       Date:  1989-09       Impact factor: 22.113

Review 10.  Chronic graft-versus-host disease.

Authors:  Stephanie J Lee; Georgia Vogelsang; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2003-04       Impact factor: 5.742

View more
  23 in total

1.  Translation, Cross-Cultural Adaptation, and Validation of the Lee Chronic Graft-versus-Host Disease Symptom Scale in a Brazilian Population.

Authors:  Clarissa Vasconcellos de Souza; Afonso Celso Vigorito; Eliana C M Miranda; Celso Garcia; Vergílio Antonio Rensi Colturato; Marcos Augusto Mauad; Maria Cláudia Rodrigues Moreira; Luis Fernando da Silva Bouzas; Simone Lermontov; Nelson Hamerschlak; Morgani Rodrigues; Jose Carlos de Almeida Barros; Ricardo Chiattone; Stephanie J Lee; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2016-04-04       Impact factor: 5.742

2.  National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report.

Authors:  Madan H Jagasia; Hildegard T Greinix; Mukta Arora; Kirsten M Williams; Daniel Wolff; Edward W Cowen; Jeanne Palmer; Daniel Weisdorf; Nathaniel S Treister; Guang-Shing Cheng; Holly Kerr; Pamela Stratton; Rafael F Duarte; George B McDonald; Yoshihiro Inamoto; Afonso Vigorito; Sally Arai; Manuel B Datiles; David Jacobsohn; Theo Heller; Carrie L Kitko; Sandra A Mitchell; Paul J Martin; Howard Shulman; Roy S Wu; Corey S Cutler; Georgia B Vogelsang; Stephanie J Lee; Steven Z Pavletic; Mary E D Flowers
Journal:  Biol Blood Marrow Transplant       Date:  2014-12-18       Impact factor: 5.742

3.  The Anatomic Distribution of Skin Involvement in Patients with Incident Chronic Graft-versus-Host Disease.

Authors:  Jocelyn S Gandelman; John Zic; Anna K Dewan; Stephanie J Lee; Mary Flowers; Corey Cutler; Joseph Pidala; Heidi Chen; Madan H Jagasia; Eric R Tkaczyk
Journal:  Biol Blood Marrow Transplant       Date:  2018-09-13       Impact factor: 5.742

4.  A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation.

Authors:  Sally Arai; Joseph Pidala; Iskra Pusic; Xiaoyu Chai; Samantha Jaglowski; Nandita Khera; Jeanne Palmer; George L Chen; Madan H Jagasia; Sebastian A Mayer; William A Wood; Michael Green; Teresa S Hyun; Yoshihiro Inamoto; Barry E Storer; David B Miklos; Howard M Shulman; Paul J Martin; Stefanie Sarantopoulos; Stephanie J Lee; Mary E D Flowers
Journal:  Clin Cancer Res       Date:  2015-09-16       Impact factor: 12.531

5.  Organ Changes Associated with Provider-Assessed Responses in Patients with Chronic Graft-versus-Host Disease.

Authors:  Paul J Martin; Barry E Storer; Jeanne Palmer; Madan H Jagasia; George L Chen; Raewyn Broady; Mukta Arora; Joseph A Pidala; Betty K Hamilton; Stephanie J Lee
Journal:  Biol Blood Marrow Transplant       Date:  2019-05-11       Impact factor: 5.742

6.  Motor ability, function, and health-related quality of life as correlates of symptom burden in patients with sclerotic chronic graft-versus-host disease receiving imatinib mesylate.

Authors:  Emily A Rosenthal; Pei-Shu Ho; Galen O Joe; Sandra A Mitchell; Susan Booher; Steven Z Pavletic; Kristin Baird; Edward W Cowen; Leora E Comis
Journal:  Support Care Cancer       Date:  2019-12-06       Impact factor: 3.603

7.  Prevalence of isolated joint involvement in chronic graft-versus-host disease: comment on the article by Inamoto et al.

Authors:  Zoya Kuzmina; Galen O Joe; Kristin Baird; Edward W Cowen; Haley B Naik; Seth M Steinberg; Lauren Curtis; Leora E Comis; Steven Z Pavletic
Journal:  Arthritis Rheumatol       Date:  2014-09       Impact factor: 10.995

Review 8.  Classification systems for chronic graft-versus-host disease.

Authors:  Stephanie J Lee
Journal:  Blood       Date:  2016-11-07       Impact factor: 22.113

Review 9.  Physical function and quality of life in patients with chronic GvHD: a summary of preclinical and clinical studies and a call for exercise intervention trials in patients.

Authors:  C Fiuza-Luces; R J Simpson; M Ramírez; A Lucia; N A Berger
Journal:  Bone Marrow Transplant       Date:  2015-09-14       Impact factor: 5.483

Review 10.  Quality of Life in the Chronic GVHD Consortium Cohort: Lessons Learned and the Long Road Ahead.

Authors:  Christa Krupski; Madan Jagasia
Journal:  Curr Hematol Malig Rep       Date:  2015-09       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.